KNSA Q2 2022 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$27M+250.1% YoY

Gross Profit

$17M63.7% margin

Operating Income

-$19M-71.8% margin

Net Income

-$20M-74.1% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

-16.2%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$211M

Total Liabilities

$57M

Stockholders' Equity

$153M

Cash & Equivalents

$94M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$8M	+250.1%
Gross Profit	$17M	$4M	+306.8%
Operating Income	-$19M	-$41M	+52.2%
Net Income	-$20M	-$42M	+51.9%

Revenue Segments

Product

$27M100%